Skip to main content
. 2014 Apr 28;16(11):1530–1540. doi: 10.1093/neuonc/nou060

Table 1.

Baseline patient characteristics (n = 5029) and hospitalization burden

Characteristic No. (%) Percent Patients Spending ≥25% of Remaining Life Hospitalized
All patients 5029 (100) 21.7
Age at diagnosis, y
 65 to ≤74 2597 (51.6) 18.2
 75 to ≤84 2038 (40.5) 25.8
 85+ 394 (7.8) 24.4
Gender
 Male 2595 (51.6) 21.7
 Female 2434 (48.4) 21.7
Race/ethnicity
 White, non-Hispanic 4441(88.3) 21.1
 Hispanic 280 (5.6) 23.6
 Black 187 (3.7) 33.7
 Asian 67 (1.3) 19.4
 Other 54 (1.1) 24.1
Marital status
 Married 3044 (60.5) 20.3
 Unmarried 638 (12.7) 23.4
 Unknown 1347 (26.8) 24.1
Modified Charlson comorbidity score (13)
 0 3077 (61.2) 18.7
 1 1280 (25.5) 22.7
 2+ 672 (13.4) 33.8
Year of diagnosis
 1999–2001 1383 (27.5) 21.7
 2002–2004 1835 (36.5) 21.6
 2005–2007 1811 (36.0) 21.9
Census tract income level
 Lower income (<median) 1733 (34.5) 22.3
 Higher income (≥median) 3296 (65.5) 21.4
SEER registry region
 Northeast 364 (7.2) 20.9
 South 520 (10.3) 19.0
 Midwest 804(16.0) 24.1
 West 3341(66.4) 21.7
Tumor location
 1 brain lobe 3752 (74.6) 21.0
 2+ brain lobes 941 (18.7) 24.8
 Other 336 (6.7) 21.7
Surgery
 Extensive (GTR) 1293 (25.7) 17.1
 Limited (biopsy/STR) 3736 (74.3) 23.3
Radiotherapy delivered
 Yes 3637 (72.3) 16.3
 No 1392 (27.7) 36.0
Temozolomide delivered
 Yes 880 (17.5) 6.1
  Before March 2005 402 (8.0)
  March 2005 or later 478 (9.5)
 No 4149 (82.5) 25.0
Other chemotherapy delivered
 Yes 1022 (20.3) 10.5
 No 4007 (79.7) 24.6
Discharge disposition after index hospitalization for GBM diagnosis
 Home 2300 (45.7) 11.1
 Home with services 588 (11.7) 14.6
 Rehabilitation 483 (9.6) 33.1
 ICF/SNF 921 (18.3) 30.6
 Hospice 182 (3.6) 36.3
 Expired 132 (2.6) 100.0
Cumulative days hospitalized, including index hospitalization and all rehospitalizations, median (IQR) 15 (8–26) 25 (16–39)

Abbreviations: GTR, gross total resection; STR, subtotal resection; ICF, intermediate care facility; SNF, skilled nursing facility; IQR, interquartile range.